GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zoetis Inc (BSP:Z1TS34) » Definitions » Inventories, Inventories Adjustments

Zoetis (BSP:Z1TS34) Inventories, Inventories Adjustments : R$0 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Zoetis Inventories, Inventories Adjustments?

Zoetis's Inventories, Inventories Adjustments for the quarter that ended in Dec. 2023 was R$0 Mil.


Zoetis Inventories, Inventories Adjustments Historical Data

The historical data trend for Zoetis's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zoetis Inventories, Inventories Adjustments Chart

Zoetis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Inventories Adjustments
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Zoetis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Zoetis Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


Zoetis (BSP:Z1TS34) Business Description

Industry
Traded in Other Exchanges
Address
10 Sylvan Way, Parsippany, NJ, USA, 07054
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Zoetis (BSP:Z1TS34) Headlines

No Headlines